PCF Helps Fund 2 Centers of Excellence to Treat Veterans With Prostate Cancer
News
The Prostate Cancer Foundation (PCF) has committed $5 million to support the launch of two new Centers of Excellence that will ... Read more
Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers
News
The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of ... Read more
AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA
News
An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has ... Read more
UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men
News
Enrollment has resumed in a five-year U.K. study investigating genetic factors behind the higher risk of prostate cancer in men of ... Read more
European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations
News
The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the ... Read more
Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC
News
A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, ... Read more
CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial
News
A heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC) showed significant benefits, including a 94% decrease in the levels of ... Read more
FDA Clears Ezra Prostate AI, a First for Cancer Imaging
News
The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the ... Read more
New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study
News
A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company ... Read more
ADT Not Needed With Radiation in Favorable Intermediate-Risk PC
News
Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate ... Read more
Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds
News
Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with ... Read more
Trial to Test Focal Laser Ablation Therapy for Localized Prostate Cancer
News
An investigator-initiated trial soon will evaluate Clinical Laserthermia Systems’ Tranberg Thermal therapy, a focal ablation therapy, for the treatment of prostate ... Read more